• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于结构的腺苷受体拮抗剂亚型选择性预测。

Structure based prediction of subtype-selectivity for adenosine receptor antagonists.

机构信息

University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, 9500 Gilman Drive, MC-0747, La Jolla, CA 92093, USA.

出版信息

Neuropharmacology. 2011 Jan;60(1):108-15. doi: 10.1016/j.neuropharm.2010.07.009. Epub 2010 Jul 15.

DOI:10.1016/j.neuropharm.2010.07.009
PMID:20637786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2980563/
Abstract

One of the major hurdles in the development of safe and effective drugs targeting G-protein coupled receptors (GPCRs) is finding ligands that are highly selective for a specific receptor subtype. Structural understanding of subtype-specific binding pocket variations and ligand-receptor interactions may greatly facilitate design of selective ligands. To gain insights into the structural basis of ligand subtype selectivity within the family of adenosine receptors (AR: A(1), A(2A), A(2B), and A(3)) we generated 3D models of all four subtypes using the recently determined crystal structure of the A(A2)AR as a template, and employing the methodology of ligand-guided receptor optimization for refinement. This approach produced 3D conformational models of AR subtypes that effectively explain binding modes and subtype selectivity for a diverse set of known AR antagonists. Analysis of the subtype-specific ligand-receptor interactions allowed identification of the major determinants of ligand selectivity, which may facilitate discovery of more efficient drug candidates.

摘要

在开发针对 G 蛋白偶联受体 (GPCR) 的安全有效的药物时,主要障碍之一是寻找对特定受体亚型具有高选择性的配体。对亚型特异性结合口袋变化和配体-受体相互作用的结构理解,可以极大地促进选择性配体的设计。为了深入了解腺苷受体 (AR:A(1)、A(2A)、A(2B)和 A(3)) 家族中配体亚型选择性的结构基础,我们使用最近确定的 A(A2)AR 晶体结构作为模板,生成了所有四种亚型的 3D 模型,并采用配体指导的受体优化方法进行了细化。这种方法产生了 AR 亚型的 3D 构象模型,有效地解释了一组不同的已知 AR 拮抗剂的结合模式和亚型选择性。对亚型特异性配体-受体相互作用的分析确定了配体选择性的主要决定因素,这可能有助于发现更有效的候选药物。

相似文献

1
Structure based prediction of subtype-selectivity for adenosine receptor antagonists.基于结构的腺苷受体拮抗剂亚型选择性预测。
Neuropharmacology. 2011 Jan;60(1):108-15. doi: 10.1016/j.neuropharm.2010.07.009. Epub 2010 Jul 15.
2
Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode.通过基于结构和配体的联合方法发现新型腺苷受体拮抗剂,并通过分子动力学研究配体结合模式。
J Chem Inf Model. 2018 Apr 23;58(4):794-815. doi: 10.1021/acs.jcim.7b00455. Epub 2018 Mar 19.
3
Structure-based virtual screening discovers potent and selective adenosine A receptor antagonists.基于结构的虚拟筛选发现了强效和选择性的腺苷 A 受体拮抗剂。
Eur J Med Chem. 2023 Sep 5;257:115419. doi: 10.1016/j.ejmech.2023.115419. Epub 2023 May 1.
4
Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A(1), A (2A), A (2B), and A (3) receptor antagonists.基于配体、结构和药效团的分子指纹:以腺苷 A(1)、A (2A)、A (2B) 和 A (3) 受体拮抗剂为例。
J Comput Aided Mol Des. 2012 Nov;26(11):1247-66. doi: 10.1007/s10822-012-9612-8. Epub 2012 Oct 12.
5
Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists.从对接至模型看配体的选择性限制:A(1) 腺苷受体拮抗剂的计算机筛选。
PLoS One. 2012;7(11):e49910. doi: 10.1371/journal.pone.0049910. Epub 2012 Nov 21.
6
G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.G 蛋白偶联腺苷(P1)和 P2Y 受体:配体设计和受体相互作用。
Purinergic Signal. 2012 Sep;8(3):419-36. doi: 10.1007/s11302-012-9294-7. Epub 2012 Feb 29.
7
Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms.腺苷受体突变的结构映射:配体结合和信号转导机制。
Trends Pharmacol Sci. 2018 Jan;39(1):75-89. doi: 10.1016/j.tips.2017.11.001. Epub 2017 Dec 5.
8
Medicinal chemistry of adenosine, P2Y and P2X receptors.腺苷、P2Y 和 P2X 受体的药物化学
Neuropharmacology. 2016 May;104:31-49. doi: 10.1016/j.neuropharm.2015.12.001. Epub 2015 Dec 12.
9
Recent developments in adenosine receptor ligands and their potential as novel drugs.腺苷受体配体的最新进展及其作为新型药物的潜力。
Biochim Biophys Acta. 2011 May;1808(5):1290-308. doi: 10.1016/j.bbamem.2010.12.017. Epub 2010 Dec 23.
10
A(3) adenosine receptor ligands: history and perspectives.A(3) 腺苷受体配体:历史与展望
Med Res Rev. 2000 Mar;20(2):103-28. doi: 10.1002/(sici)1098-1128(200003)20:2<103::aid-med1>3.0.co;2-x.

引用本文的文献

1
Targeting the inter-monomeric space of TNFR1 pre-ligand dimers: A novel binding pocket for allosteric modulators.靶向肿瘤坏死因子受体1(TNFR1)配体前二聚体的单体间空间:变构调节剂的新型结合口袋。
Comput Struct Biotechnol J. 2025 Mar 28;27:1335-1341. doi: 10.1016/j.csbj.2025.03.046. eCollection 2025.
2
Orphan G protein-coupled receptors: the ongoing search for a home.孤儿G蛋白偶联受体:仍在寻找归属
Front Pharmacol. 2024 Feb 29;15:1349097. doi: 10.3389/fphar.2024.1349097. eCollection 2024.
3
Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5.拮抗剂与趋化因子受体CCR2和CCR5相互作用的分子决定因素
bioRxiv. 2024 Feb 12:2023.11.15.567150. doi: 10.1101/2023.11.15.567150.
4
Milk kefir drink may not reduce depression in patients with non-alcoholic fatty liver disease: secondary outcome analysis of a randomized, single-blinded, controlled clinical trial.牛奶开菲尔饮品可能无法减轻非酒精性脂肪性肝病患者的抑郁症状:一项随机、单盲、对照临床试验的次要结局分析。
BMC Nutr. 2023 Jun 29;9(1):80. doi: 10.1186/s40795-023-00732-x.
5
Distinct activation mechanisms regulate subtype selectivity of Cannabinoid receptors.不同的激活机制调节大麻素受体的亚型选择性。
Commun Biol. 2023 May 5;6(1):485. doi: 10.1038/s42003-023-04868-1.
6
Irreversible Antagonists for the Adenosine A Receptor.腺苷 A 受体的不可逆拮抗剂。
Molecules. 2022 Jun 13;27(12):3792. doi: 10.3390/molecules27123792.
7
Investigation of Key Signaling Pathways Associating miR-204 and Common Retinopathies.探讨与 miR-204 和常见视网膜病变相关的关键信号通路。
Biomed Res Int. 2021 Oct 4;2021:5568113. doi: 10.1155/2021/5568113. eCollection 2021.
8
Adenosine Receptor Ligands: Coumarin-Chalcone Hybrids as Modulating Agents on the Activity of ARs.腺苷受体配体:香豆素-查尔酮杂合体作为 ARs 活性调节剂。
Molecules. 2020 Sep 19;25(18):4306. doi: 10.3390/molecules25184306.
9
Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design.嘌呤能信号转导:G 蛋白偶联受体结构对合理药物设计的影响。
ChemMedChem. 2020 Nov 4;15(21):1958-1973. doi: 10.1002/cmdc.202000465. Epub 2020 Sep 18.
10
Performance of virtual screening against GPCR homology models: Impact of template selection and treatment of binding site plasticity.针对 GPCR 同源模型的虚拟筛选性能:模板选择和结合位点可塑性处理的影响。
PLoS Comput Biol. 2020 Mar 13;16(3):e1007680. doi: 10.1371/journal.pcbi.1007680. eCollection 2020 Mar.

本文引用的文献

1
Structure-based discovery of A2A adenosine receptor ligands.基于结构的 A2A 腺苷受体配体的发现。
J Med Chem. 2010 May 13;53(9):3748-55. doi: 10.1021/jm100240h.
2
Ligand binding and subtype selectivity of the human A(2A) adenosine receptor: identification and characterization of essential amino acid residues.人 A(2A) 腺苷受体的配体结合和亚型选择性:必需氨基酸残基的鉴定和特征描述。
J Biol Chem. 2010 Apr 23;285(17):13032-44. doi: 10.1074/jbc.M109.096974. Epub 2010 Feb 10.
3
Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists.基于结构的新型腺苷 A(2A)受体拮抗剂化学型的发现。
J Med Chem. 2010 Feb 25;53(4):1799-809. doi: 10.1021/jm901647p.
4
GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex.用于配体筛选的 GPCR 三维同源模型:从对腺苷 A2a 受体复合物的盲预测中获得的经验教训。
Proteins. 2010 Jan;78(1):197-211. doi: 10.1002/prot.22507.
5
Adenosine A2A receptors and Parkinson's disease.腺苷A2A受体与帕金森病。
Handb Exp Pharmacol. 2009(193):589-615. doi: 10.1007/978-3-540-89615-9_18.
6
Adenosine receptors and the central nervous system.腺苷受体与中枢神经系统
Handb Exp Pharmacol. 2009(193):471-534. doi: 10.1007/978-3-540-89615-9_16.
7
Adenosine receptors and cancer.腺苷受体与癌症。
Handb Exp Pharmacol. 2009(193):399-441. doi: 10.1007/978-3-540-89615-9_14.
8
Adenosine receptors and asthma.腺苷受体与哮喘
Handb Exp Pharmacol. 2009(193):329-62. doi: 10.1007/978-3-540-89615-9_11.
9
Adenosine receptors and inflammation.腺苷受体与炎症
Handb Exp Pharmacol. 2009(193):215-69. doi: 10.1007/978-3-540-89615-9_8.
10
Adenosine receptors and reperfusion injury of the heart.腺苷受体与心脏再灌注损伤
Handb Exp Pharmacol. 2009(193):189-214. doi: 10.1007/978-3-540-89615-9_7.